Skip to Content

Lanreotide Pregnancy and Breastfeeding Warnings

Lanreotide is also known as: Somatuline Depot

Medically reviewed on January 26, 2018.

Lanreotide Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

AU TGA pregnancy category: C
US FDA pregnancy category: C

Animal studies showed decreased fetal growth and embryo/fetal survival, and increased skeletal/soft tissue abnormalities. Animal fertility was decreased, probably due to the suppression of growth hormone. There are no controlled data in human pregnancy.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Lanreotide Breastfeeding Warnings

An animal study during lactation showed growth retardation of the offspring prior to weaning, and reduced memory and learning test results in male offspring.

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Use is contraindicated. (AU)

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Somatuline Depot (lanreotide)." Tercica Inc, Brisbane, CA.

References for breastfeeding information

  1. "Product Information. Somatuline Depot (lanreotide)." Tercica Inc, Brisbane, CA.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide